Mastaplex Ltd is poised to become a leading provider of point-of-care diagnostic tests for mastitis in dairy cows, supporting veterinarians and farmers around the globe with antibiotic treatment decisions. The company’s products and services support disease management, improved food quality, and combat against antimicrobial resistance. It has developed a proprietary mastitis testing device Mastatest which provided faster and more precise mastitis diagnosis on farm. A cloud-based IT solution, Mastaplex is able to advise a farmer which cow has which bug within 24 hours, helping decrease antibiotic use.

Mastaplex was founded by Olaf Bork and is based in the heart of the University of Otago campus within the Centre for Innovation. This position provides access to world class research infrastructure and embeds Mastaplex Ltd in a vibrant, well-supported entrepreneurial space. Mastaplex Ltd was incubated in 2015 through WNT Ventures with the support of Callaghan Innovation and through seed funding from Pacific Channel with the goal to accelerate innovation and to build a global company.

Enterprise Angels first invested in Mastaplex in 2017 and it is part of the EA Fund 2 portfolio.